Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12-month price targets for Amneal Pharmaceuticals' shares. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 135.0% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 at the start of the year. Since then, AMRX stock has increased by 17.6% and is now trading at $2.34.
View the best growth stocks for 2023 here.

Amneal Pharmaceuticals saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 7,740,000 shares, an increase of 142.6% from the December 15th total of 3,190,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the days-to-cover ratio is presently 6.8 days. Currently, 7.8% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our AMRX earnings forecast.

Amneal Pharmaceuticals will be holding an earnings conference call on Thursday, March 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 866-813-9403 with passcode "942331".

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced its quarterly earnings results on Friday, November, 4th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by $0.04. The firm earned $545.56 million during the quarter, compared to the consensus estimate of $564.58 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 57.89% and a negative net margin of 6.17%.

Amneal Pharmaceuticals issued an update on its FY22 earnings guidance on Tuesday, January, 10th. The company provided earnings per share guidance of $0.65-0.70 for the period, compared to the consensus estimate of $0.66. The company issued revenue guidance of $2.15-2.25 billion, compared to the consensus revenue estimate of $2.18 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.52%), Strs Ohio (0.07%), Assenagon Asset Management S.A. (0.02%), Hennion & Walsh Asset Management Inc. (0.02%), Private Advisor Group LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul M Meister and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $2.34.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $710.40 million and generates $2.09 billion in revenue each year. The company earns $10.62 million in net income (profit) each year or ($0.87) on an earnings per share basis.

The company employs 7,000 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.